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De01-1
BEST TIMING OF LT FOR HCC AFTER
HEPATECTOMY - AFTER
RECURRENCE (SALVAGE)
See-Ching Chan
The University of Hong Kong, China
Salvage liver transplantation is a treatment for recur-
rent hepatocellular carcinoma after resection or abla-
tion has failed and become unfeasible. Research on this
subject is difficult given the heterogeneity. In patient
population, tumor status, and therapeutic standards
and policies of different centers. Nevertheless, studies
have shown that when the status of the recurrent tumor
is within standard criteria, an acceptably low recurrence
rate after salvage transplantation can be expected.
However, tumor status at the time of primary treat-
ment has not been analyzed, yet it cannot be ignored,
especially when recurrence requiring salvage transplan-
tation occurs not long after primary treatment. Besides
those who receive suboptimal treatment for hepatocel-
lular carcinoma, recipients often have more aggressive
tumors or cirrhotic livers and thus are prone to develop
new primaries. Case selection based on history of
tumor status and time of tumor recurrence is crucial.
The effectiveness of salvage liver transplantation also
has a bearing on embarking on primary or upfront
liver transplantation for small resectable hepatocellular
carcinomas, which gives some survival advantages. An
intensive follow-up program after primary treatment
enables early detection of tumor recurrence. Wearing
down of enthusiasm for living donor donation and
poor supply of deceased donor grafts also hamper the
efficacy of salvage liver transplantation.
De02-1
MINIMALLY INVASIVE
PANCREATECTOMY FOR SMALL
PANCREATIC ADENOCARCINOMA
Michael L. Kendrick
Mayo Clinic, U.S.A.
Pancreatic resection remains the sole treatment option
with the potential for cure in patients with pancreatic
cancer. Despite this, only a small fraction of patients
are cured with resection due to the early occurrence of
occult metastatic disease prior to clinical presentation.
Limitations of pancreatic resection include significant
morbidity that can impair quality of life and the delay
or prevent the patient’s opportunity to receive adjuvant
treatment. Attempts to reduce the morbidity and long
convalescence associated with pancreatic resection are
thus particularly important in patients with cancer. Lit-
erature and Institutional Review. Several studies have
now confirmed the typical advantages of laparoscopic
approaches in patients undergoing pancreatectomy with
regard to operative blood loss, postoperative pain,
wound morbidity and hospital stay. These advantages
will provide significant benefit to patients with malig-
nancy; however, assuring that equivalent oncologic
outcomes can be obtained with minimally invasive
approaches is of paramount importance. Unfortu-
nately, large adequately powered or randomized trials
are not yet available. Current series of laparoscopic
pancreatic resection for malignancy are limited by small
numbers of patients, potential selection bias, and lack
of adequate follow-up. While long-term outcomes in
larger series are eagerly awaited, current evaluation is
insufficient to critically assess the adequacy of oncolog-
ic resection and long-term outcomes. Therefore, the
clear impact of minimally invasive approaches on the
oncologic outcomes is poorly defined for patients with
pancreatic malignancy. Discounting the established
advantages and the potential for equivalent or even
superior oncologic outcomes due to lack of randomized
trials is detrimental to progress. Thus, surrogates to
evaluate the efficacy and quality of oncologic resection
have been described including: number of lymph nodes
harvested, rate of margin negative resection, estimated
operative blood loss, need for transfusion, progression-
free and short-term survival. Several comparative trials
have now suggested that the oncologic resection is simi-
lar for laparoscopic compared to open distal pancrea-
tectomy. For pancreaticoduodenectomy, data is more
limited and robust direct comparisons are lacking. Our
institution has an increasing experience with laparo-
scopic approaches in pancreatic resection for both
benign and malignant indications. This lecture will crit-
ically review the current literature and discuss our insti-
tutional experience of laparoscopic resection for
pancreatic adenocarcinoma. Our data suggests that lap-
aroscopic approaches provide comparable oncologic
outcomes to open approaches while providing advanta-
ges typical of minimally invasive approaches. Contin-
ued and careful scrutiny of the laparoscopic
approaches for pancreatic resection is imperative to
assure the maintenance of sound oncologic principles
that have been established with open approaches.
De02-2
MINIMALLY INVASIVE
PANCREATECTOMY FOR SMALL
PANCREATIC ADENOCARCINOMA:
“NO”
Akimasa Nakao
Nagoya Central Hospital, Japan
Pancreatic cancer remains a dismal disease among the
digestive cancers. Although open pancreatic cancer sur-
gery has been developing and operative mortality has
decreased remarkably over the past 30 years. Postoper-
ative survival has been increasing slightly using adju-
vant chemotherapy. However, the early diagnosis of
pancreatic cancer is still difficult. Minimally invasive
pancreatic cancer surgery using laparoscopy or robotics
has been developing in recent years also. However, the
efficacy of minimal invasive surgery for pancreatic can-
cer has not yet been clarified, and the definition of
early pancreatic cancer has not yet been decided. In
this debate session, I studied 288 (head 228, body and
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tail 60) resected cases of pancreatic cancer in the past
10 years and especially analyzed TS1 tumors of less
than 2 cm in diameter. According to the JPS classifica-
tion, TS1 pancreatic head cancer (n=45) showed lymph
node metastasis with a high incidence of 62.2% (N1:
33.3%, N2: 24.4%, N3: 4.4%). Extra pancreatic nerve
plexus invasion was observed in 3 of 45 patients with
TS1 tumor. Moreover, portal vein invasion was
observed in 9 of 45 (20%) patients with TS1 tumor. I
have been performing isolated pancreatectomy which
involves the use of the non-touch isolation technique in
pancreatectomy. The most important first step of this
operation is the mesenteric (Nakao) approach, which is
performed at the beginning of pancreatoduodenectomy.
This approach is the systematic connective tissue resec-
tion of the root of the mesentery including lymph
nodes around the SMA, and the inferior pancreatoduo-
denal artery is ligated and divided. The cancer-free
margin and resectability are decided at the first step.
Kocher’s maneuver is not performed. By this approach,
portal vein resection and end-end anastomosis can be
done easily, making it the most important procedure in
pancreatoduodenectomy. If minimally invasive pancrea-
tectomy can be performed with this approach, I will
agree the minimally invasive surgery. However, I have
not yet watched the mesenteric approach by minimally
invasive surgery. Therefore I have to say “No”. Small
pancreatic cancer, Minimally invasive, Mesenteric
approach, laparoscopic surgery, Robotic surgery
De03-1
HEPATOPANCREATODUODENECTOMY
FOR CHOLANGIOCARCINOMA
Masato Nagino
Nagoya University Graduate School of Medicine, Japan
Cholangiocarcinomas often exhibit an extensive ductal
spread invading from the hepatic hilus to the lower bile
duct, and such tumors can be completely resected only
by hepatopancreatoduodenectomy (HPD). Early experi-
ences with HPD were associated with high mortality
and morbidity, leading to an underestimation of the
survival benefit of HPD. In this lecture, we outline our
experiences with HPD as a treatment for cholangiocar-
cinoma and appraise the clinical significance of this
challenging procedure. We retrospectively reviewed the
medical records of 93 patients with cholangiocarcinoma
who underwent HPD from January 1992 to September
2012. There were 65 men and 28 women, with a mean
age of 6610 years (range, 25 to 82 years). Of these, 91
(97.8%) underwent preoperative biliary drainage,
including percutaneous transhepatic biliary drainage in
56, endoscopic naso-biliary drainage in 32, endoscopic
biliary stent in 2, and self-expanding metallic stent in 1.
Main tumor location was perihilar in 69 and distal in
22. The remaining 2 patients were the case of recurrent
distal cholangiocarcinoma after bile duct resection with
cholangiojejunostomy. The type of hepatectomy was
right hemihepatectomy in 57, left trisectionectomy in
14, left hemihepatectomy in 13, right trisectionectomy
in 3, and other hepatectomies in 6; overall, major hepa-
tectomy was performed in 87 patients (93.5%). and
combined vascular resection was performed in 26
patients (30.6%). Combined vascular resection was per-
formed in 35 (37.6%) patients, including portal vein
resection alone in 24, hepatic artery resection alone in
4, and simultaneous portal vein and hepatic artery
resection in 7 (so-called Hepato-ligamento-pancreato-
duodenectomy; HLPD) The operating time was 764 
143 minutes (range, 530 to 1380 minutes), and blood
loss was 2725  2104 mL (range, 683 to 12688 mL).
Pancreatic fistula occurred in 67 (72.0%) patients,
including ISGPS-Grade A in 1, Grade B in 58, and
Grade C in 8. Liver failure, defined as a maximum
serum total bilirubin level of >10 mg/dL, was observed
in 10 (10.8%) patients. Two (2.2%) patients died of
postoperative complications. One nonsurvivor was a
68-year-old woman who underwent right hepatectomy
and PD. Her postoperative course was nearly satisfac-
tory, but she complained of severe upper abdominal
pain on day 54 after surgery. Urgent re-laparotomy
was conducted for jejunal perforation, but she died of
multiple organ failure on day 79 after surgery. Another
case was a 60-year-old man who underwent right hepa-
tectomy and PD with portal vein resection and recon-
struction. On day 1 after surgery, urgent re-laparotomy
was performed to remove a portal vein thrombus.
However, he died of multiple organ failure 15 days
after the initial surgery. The remaining 91 patients were
discharged from the hospital in good condition. The
overall survival rate for the 93 patients was 54.4% at
3-year, 40.0% at 5-year, and 30.0% at 10-year; actu-
ally, 14 patients survived for more than five years. The
rate of survival for the 67 patients with pM0 disease
who underwent R0 resection was the most favorable,
with 5- and 10-year survival rates of 62.0% and 52.7%,
respectively. HPD is technically demanding and associ-
ated with high morbidity. However, this surgery can be
performed with low mortality and offers a better prob-
ability of long-term survival in selected patients. As he-
patobiliary surgeons, we should consider HPD to be a
standard procedure for laterally-advanced cholangio-
carcinomas that are otherwise unresectable.
De03-2
CHOLANGIOCARCINOMA R1
RESECTION: HOW MUCH IS TOO
MUCH?
Henry Pitt
Temple University School of Medicine, U.S.A.
In North America, cholangiocarcinomas account for
nearly 3% of all gastrointestinal tumors and 10-15% of
all primary hepatobiliary malignancies. Approximately
5,000 new patients are diagnosed with cholangiocarci-
noma in the United States each year. While survival
rates have improved, optimal surgical outcomes remain
problematic. Both the location and extent of these
tumors play a key role in their resectability as well as
the adequacy of the surgical resection. Cholangiocarci-
nomas have been classified as intrahepatic, perihilar,
distal and diffuse. Perihilar cholangiocarcinomas are
more common than purely intrahepatic tumors. For
each of these subtypes, microscopic extension along the
bile duct is a major impediment to achieving an R1
resection. However, some “diffuse” tumors represnt
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the papillary subtype which have a better pronosis. Dif-
fuse tumors are the least common variety but present
the greatest challenge to this goal. The location and
extent of the tumor, both with respect to the bile duct
and to vascular invasion, dictate the magnitude of the
resection. Combined procedures, such as those that
require vascular resection, bile duct plus hepatic resec-
tion and hepatopancreatoduodenectomy (HPD), clearly
increase the risk of surgery. The American College of
Surgeon (ACS) National Quality Surgical Improvement
Program (NSQIP) is a prospective, multicenter clinical
registry that provides feedback on risk -adjusted out-
comes. From 2005 through 2009, 843 patients with
resected cholangiocarcinoma had mortality and mor-
bidity monitored through ACS-NSQIP. Mortality at
30 days was 5.4% but was highest (12.0%) for com-
bined bile duct and hepatic resection and lowest (1.2%)
for pancreatoduodenectomy (PD). Of note, no HPDs
were performed. Overall morbidity was 41.8% and
was highest for a combined bile duct and hepatic resec-
tion (47.8%) followed by pancreatoduodenectomy
(47.1%). Postoperative complications, especially sepsis
and those requiring reoperation, were independently
associated with increased odds of death (P<0.05). A
history f cardiopulmonary disease, preoperative hyper-
bilirubinemia (>3 mg/dl), thrombocytopenia and intra-
operaive transufsion of >7 U red blood cells were all
risk factors for increased mortality. In 2012 a Pancrea-
tectomy Demonstration Project also was performed
though ACS-NSQIP. During the first 7 months, 720
patients undergoing pancreatoduodenectomy (PD) were
monitored at 33 hospitals. One hundred fifty of the
patients (18.3%) also had vascular resection
(VR). When compared to the 670 PD alone patients,
the PD +VR patients had increased operative time (1
hour, P <0.05) and were more likely to require a trans-
fusion (43 vs 22%, P <0.05). Both overall (67 vs 45%)
and serious morbidity (59 vs 35%) were significantly
increased (P <0.05) in the PD+VR patients. At “high-
volume” centers these outcomes for PD+VR were
slightly worse (61 and 72%, respectively), and the trans-
fusion rate was higher (52 vs 30%, P<0.05). Thus, even
in high-volume, expert referral centers, the morbidity of
vascular resection remains high. Therefore, the decision
to perform vascular resection during a pancreatoduo-
denectomy should be undertaken with caution. In
patients with cholangiocarcinoma multiple factors influ-
ence long-term survival. Both preoperative cholangitis
and hypoalbuminemia have been correlated with
reduced long-term survival. In multiple series patients
who receive an R0, as opposed to an R1, resection have
improved survival. In addition, patients who suffer
postoperative complications have reduced long-term
survival. Unfortunately, larger operations performed to
achieve an R0 resection are associated with greater mor-
bidity and, therefore, reduced survival. Tumor stage,
also predicts survival. Finally, adjuvant chemotherapy
may improve long-term outcome whereas radiation
alone has not been proven to benefit these patients. In
summary, for a patient with a “diffuse” distal cholan-
giocarcinoma, pancreatoduodenectomy alone is a safe
operation, and the goal should be to achieve an R0
resection. However, if vascular resection is required,
postoperative morbidity is increased which, in turn,
reduces the likelihood that the patient will receive adju-
vant therapy and achieve long-term survival. In general,
in the United States the morbidity and mortality of
combined pancreatectomy and hepatectomy is felt to be
so high that the risk clearly outweighs the benefit.
De04-1
LAPAROSCOPIC LIVER
RESECTION - PRO
Daniel Cherqui
Hepatobiliary Center, France
Despite close to twenty years of development and over
3,000 reported cases internationally, laparoscopic liver
resection (LLR) remains an emerging field that should
be approached with caution by surgeons experienced in
the operative care and planning of both liver and lapa-
roscopic surgery. Only nine centers have reported series
greater than 100 patients and most centers perform less
than half of their total cases laparoscopically. We have
performed over 300 laparoscopic partial hepatectomies
which represents 23% of our hepatectomy volume. It
must be acknowledged that there are no published pro-
spective randomized comparisons with open liver resec-
tion and most data arise from case series, comparative
case match series and a few “meta-analyses”. However,
there is an exponentially growing number of abstracts
and videos submitted to international HPB congresses.
Lessons learned from this experience and that of others
is that laparoscopic liver resection is feasible and safe
in selected patients and this technique deserves a place
in the armamentarium of the liver surgeon. It is less
invasive than open operation and preserves the abdom-
inal wall, but its advantages may not be limited to
these aspects. Laparoscopy is associated with reduced
blood loss, reduced pain, quicker recovery, earlier
access to chemotherapy if needed, and it facilitates
repeat operation if needed. It may be a better technique
owing to optical magnification. Improved outcomes
and reduced morbidity have also been demonstrated in
cirrhotic patients undergoing laparoscopic resection of
small HCC. Initially limited to minor resection of small
peripheral lesions, a growing number of successful
major and/or complex laparoscopic resections are
reported, including living donor hepatectomy.
Several conditions are required for a successful LLR
program:
1. It must be developed upon a solid foundation of
open liver surgery and after competency with advanced
laparoscopic techniques has been clearly achieved,
2. State of the art technology must be available,
3. Patient selection must be accurate
4. The availability of laparoscopy should not widen the
indications for resection of asymptomatic benign
lesions
5. The rules of oncologic surgery must be followed for
minimally invasive operations, just as in their open
counterparts.
6. For a starting program, good candidates for laparo-
scopic liver resection are patients with peripheral
lesions requiring limited hepatectomy
7. Safety requires that before embarking on laparo-
scopic major or complex resection, competency with
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less technically complex LLR has been clearly achieved.
LLR has moved from infancy to adolescence. As in all
other innovations in surgery, it will grow to maturity
with sensible use, proper training and proper evalua-
tion. The new generation of surgeons who were born
and trained after the inception of laparoscopy are natu-
rally skilled and will probably bring LLR to its next
level.
De05-1
TWO-STAGE HEPATECTOMY : AN
ESTABLISHED TREATMENT FOR
EXTENSIVE BILATERAL COLORECTAL
LIVER METASTASES (CRLM)
Rene Adam
APHP Ho^pital Paul Brousse, France.
Two-stage hepatectomy has been first reported in 2000
with the aim to resect by two sequential liver resec-
tions, multinodular metastases irresectable by a single
procedure. The procedure is reserved to bilateral
CRLM when the future liver remnant after resection
has insufficient volume (< 30% of the total functional
liver) and contains more than 3 lesions and/or a maxi-
mum diameter > 3cm, a situation unfit for an efficient
radiofrequency combined to the contralateral hemihep-
atectomy. Regeneration obtained after the first hepatec-
tomy is usually boosted and oriented to the future
remnant liver by a portal embolization of the contralat-
eral liver. As LMCR are usually predominant on the
right hemiliver, the 1st procedure usually consists of a
tumor clearance of the left hemiliver with right portal
embolization, followed by a right hepatectomy as 2nd
procedure. One of the main principle of the 1st hepatec-
tomy is therefore to avoid any residual tumor on the
future remnant liver, to prevent any tumoral progres-
sion boosted by the hypertrophy induced by the contra-
lateral portal embolization
Since its initial description, more than 15 series, includ-
ing more than 350 pts have been reported with the
main following results :
- a risk of mortality of 0 to 7% (mean : 2%), mainly
observed for the second procedure,
- a morbidity of around 20% and 40% respectively for
the 1st and 2nd operation
- a failure to achieve the 2nd procedure in 20-30% of
patients mainly due to tumor progression
- a 5-year survival of 40 to 60% for patients achieving
the complete strategy, 30% on an intention-to-treat for
all patients, including those who failed the second pro-
cedure.
- Prognostic factors have included an age > 70 yrs, a
high number of metastases (≥6), the presence of extra-
hepatic disease, the preoperative use of more than 2
chemotherapy regimens, the absence of postoperative
chemotherapy. . .
- The outcome of patients having completed the two-
stage strategy is significantly improved compared to
patients receiving chemotherapy only.
Some issues are still debated concerning the use of che-
motherapy in between the two stages, the ideal timing
to perform the 2nd stage, the possibility to resect the
primary during the 1st stage
1. Two stage hepatectomy is an established strategy to
increase resectability in selected patients with advanced
bilobar disease impossible to resect in one stage even
with the help of Radiofrequency
2 .Its feasibility rate is 70-80% and excludes patients
with progressive disease who possibly would not have
really benefit from surgery.
3. Prognostic factors may help to increase this feasibil-
ity, allowing a 5-year survival rate of at least 40%,
equivalent to that of patients with less extended metas-
tastic disease.
De05-2
ASSOCIATING LIVER PARTITION AND
PORTAL VEIN LIGATION FOR STAGED
HEPATECTOMY (ALPPS): TIPS AND
TRICKS
Eduardo De Santiba~nes
Hospital Italiano de Buenos Aires, Argentina
Resection of liver tumors with curative intent remains
the treatment of choice for patients with malignant dis-
ease that offers long-term survival. Unfortunately, at
diagnosis, many patients have multiple liver lesions
which often preclude a complete resection. During the
last years, new multidisciplinary therapies have been
proposed to increase safely the resectability rate in
patients with initially nonresectable liver tumors. How-
ever, the intent to preserve an adequate liver remnant
to avoid posthepatectomy liver failure (PHLF) repre-
sents the main limitation to achieve atumor-free margin
after resection of primary or metastatic liver lesions. To
minimize the risk of PHLF in patients with a marginal
future liver remnant (FLR), portal vein embolization
or portal vein ligation (PVL) in combination or not
with two-stage procedures has been widely used to
increase FLR volume and therefore expand the poten-
tially resectable pool of patients. Associating liver parti-
tion and PVL for staged hepatectomy (ALPPS) has
recently been described as an advantageous strategy to
induce a rapid and marked increase in FLR volume
with promising preliminary results. In the present man-
uscript, we aim to describe in detail our current surgi-
caltechnique and results with the ALPPS procedure,
adding some surgical tips and tricks learned after our
initial experience with this new two-stage approach.
During the first stage, liver partition and PVL of the
diseased hemiliver are performed. The completion sur-
gery is carried out after volumetric studies have demon-
strated a sufficient FLR and provided the patient is in
good condition. This is usually achieved after 7 days.
In the second step, the patient undergoes a completion
surgery with right hepatectomy, right trisectionectomy,
or left trisectionectomy. Fifteen patients with advanced
liver tumors were treated. Nine patients were males and
the mean age was 54 years old. The mean difference
between the preoperative and postoperative FLR vol-
ume was 303 ml (p<0.001), which represented A mean
volume increase of 78.4 %. All resections were R0.
Morbidity and mortality rates were 53 and 0 %,
respectively. The average hospital stay was 19 days.
The presented technique was feasible and safe in the
hands of experienced hepatobiliary surgeons, with
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satisfactory short-term results. It induces rapid liver
hypertrophy and at the same time it offers the possibil-
ity of cure to patients previously declared unresectable.
De07-2
PREOPERATIVE TREATMENT FOR
MARGINALLY-RESECTABLE
ADVANCED HCC: CON
Katsuhiko Yanaga
Jikei University School of Medicine, Japan
Hepatocellular carcinoma (HCC) is one of the most
frequent malignancies in the world, for which hepatic
resection or liver transplantation remains the most
effective treatment. In the 18th Nationwide Follow-Up
Survey of Primary Liver Cancer in Japan, 19,499
patients with HCC were newly registered between Janu-
ary 2004 and December 2005. Of these, 5,646 patients
underwent hepatic resection, and 148 patients under-
went liver transplantation. Although operative mortal-
ity of elective hepatic resection in patients with HCC
has been minimized, recurrence of HCC remains high.
Factors associated with such recurrence include tumor
size, vascular invasion and number of lesions. However,
the usefulness of preoperative treatment for tumor
down-staging including transarterial chemoemboliza-
tion (TACE) and hepatic arterial infusion chemother-
apy (HAIC) remains controversial. National
Comprehensive Cancer Network Clinical Practice
Guideline in Oncology for Hepatobiliary Cancers Ver-
sion 2.2013 recommends that hepatic resection is indi-
cated as a potentially curative option in patients with
adequate liver function, solitary mass without major
vascular invasion, and adequate future liver remnant,
which is controversial in patients with limited and
respectable multifocal disease, or major vascular inva-
sion. Patients meeting the United Network for Organ
Sharing Criteria (single lesion less than 5 cm, or 2 or 3
lesions less than 3cm) are recommended to undergo
cadaveric or live donor liver transplantation. Japanese
Clinical Practice Guidelines for Hepatocellular Carci-
noma do not recommend TACE or HAIC as preopera-
tive treatment for resectable HCC. In Nationwide
Follow-Up Survey in Japan from 1994 to 2005, the 1-,
3-, and 5-year cumulative survival rates of HCC treated
with hepatic resection were 88.2%, 69.5%, and 54.2%,
respectively. As to the outcome of marginally resectable
advanced HCC, the 1-, 3-, and 5-year survival in
patients with 3 or more lesions were 75.7%, 48.1%,
and 30.6%, and those in patients with major portal
vein invasion were 52.1%, 26.4%, and 18.3%, respec-
tively. We reviewed our experience with 213 hepatic
resections for HCC during January 2000 and October
2013. The 1-, 3-, and 5-year survival were 91.9%,
78.4%, and 70.4%, respectively. Of these, 37 patients
received preoperative TACE. The 1-, 3-, and 5-year
survival in patients with preoperative TACE were
88.7%, 62.3%, and 52.0%, while those in patients with-
out preoperative TACE were 92.6%, 81.9%, and
74.4%, respectively. As to the outcome of marginally
resectable advanced HCC in our department, the 1-, 3-,
and 5-year survival with 3 or more lesions were 95.0%,
48.0%, and 32.0%, and those with major portal vein
invasion were 33.3%, 0%, and 0%, respectively. Also,
26 of 77 patients with recurrent HCC underwent
repeated hepatic resection, for whom the 1-, 3-, and 5-
year survival were 95.7%, 86.5%, and 86.5%, respec-
tively. The results of our series suggest that, in order to
improve therapeutic outcome of HCC after hepatic
resection, postoperative close follow-up and mainte-
nance of remnant liver function that reserve repeated
hepatic resection as an option for recurrence seem
important, while preoperative treatment of HCC does
not seem to improve the outcome of HCC after hepatic
resection.
De08-1
TREATMENT OF PANCREATIC CYSTIC
TUMOR: EUS-GUIDED ABLATION
Dong-Wan Seo
Asan Medical Center, Ulsan University, Korea
Cystic lesions of the pancreas are detected more and
more with the advancement of imaging modalities. His-
tological diagnosis of pancreatic cysts can be diverse:
pseudocyst, mucinous cystic neoplasm, serous cystic
neoplasm, intraductal papillary mucinous neoplasm,
solid pseudopapillary neoplasm, cystic lymphangioma,
lymphoepithelial cyst, etc. The differential diagnosis
and management of pancreatic cystic lesion become
quite burdensome for clinicians because most of the
lesions are small, asymptomatic and showing benign
nature. With conventional imaging modalities such as
ultrasonography, CT or MRI, the location, contour
and size of pancreatic cystic lesion can be examined.
Endoscopic ultrasonography (EUS) can detect the pres-
ence septum, mural nodule, number of locules and wall
thickness more accurately. By adding EUS-guided cys-
tic fluid examination, we can analyze the level of amy-
lase, lipase, and tumor markers such as CEA or Ca19-
9. Cytologic examination can also be performed
although the yield is low. All these information can be
helpful for the differential diagnosis among mucinous
cystic tumor, non-mucinous cystic tumor and pseudo-
cyst. Typical cases can be differentiated by combined
clinical, radiological, endosonographic and biochemical
characteristics. Regarding treatment, pancreatic
pseudocyst can be effectively managed by EUS-guided
cystogastrostomy or cystoduodenostomy. Malignant
mucinous cystic tumor should be treated by surgical
resection if it is resectable. However, a significant por-
tion of cystic lesions can not be differentiated accu-
rately even after extensive medical work-up. Surgical
resection has been mainstay of therapy when mucinous
cystic neoplasm is suspected. Based on surgical data,
about one-thirds of resected cases were benign lesions
in which surgical resection of pancreas was unneces-
sary. If we have a non-invasive local treatment modal-
ity for these benignly behaving lesions, it would be
beneficial for patients. As a novel approach, EUS-
guided ethanol lavage with/without paclitaxel injection
has been tried for benign pancreatic cystic tumor. Preli-
minary reports showed the safety and feasibility of
EUS-guided pancreatic cystic tumor (PCT) treatment.
Treatment responses varied among studies as previous
studies involved small number of patients and short-
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term follow-up. Our group conducted a series of studies
to evaluate the technical feasibility, safety and thera-
peutic efficacy of EUS-guided PCT ablation. At first,
we conducted a pilot study and selected 14 patients
with PCT received EUS-guided ethanol lavage and pac-
litaxel injection (EUS-EP) and observed for 6 months.
Complete resolution (CR) of PCT was observed in 11
patents and partial resolution (PR) in 2 patients. Next
step study was focused on septated PCT and we
observed 60% of CR and 20% of PR. Encouraged by
above results, we conducted a long-term follow-up
study after EUS-EP of PCT. Fifty-one patients were
enrolled for EUS-EP by the following inclusion criteria;
1) uni- or oligolocular cyst, 2) indeterminate tumors for
which EUS-FNA was required, and 3) PCTs showing
size growth during the observation period. Under EUS-
guidance, cyst fluid aspiration, ethanol lavage and
injection of paclitaxel were performed. Twenty PCTs
were oligolocular. Mean CEA level was 463 ng/mL (1-
8190). The median follow-up was 20.6 months. Mean
volume of PCT decreased from 14.09 mL to 3.31 mL.
CR was observed in 28 patients, PR in 6 patients, and
a cyst persisted in 12 patients. Splenic vein thrombosis
as procedure-related complication occurred in 1 patient.
EUS-EP appears to be a safe and effective method for
treating PCT.
De09-1
REVERSE STRATEGY FOR
COLORECTAL CANCER WITH
SYNCHRONOUS LIVER METASTASES
Gilles Mentha
University Hospitals of Geneva, Switzerland
The growing efficacy of chemotherapy, accompanied by
advances in liver surgery techniques and interventional
radiology (hemi-portal embolization, radiofrequency
thermal ablation), led to the development of new strate-
gies to increase the number of patients who may benefit
from a curative approach. One of these strategies is the
so-called reverse treatment of advanced synchronous
colorectal liver metastases(CRLM). In this strategy, a
highly effective neoadjuvant chemotherapy directed
against the liver metastases is given first, liver surgery
is done next, and the colorectal resection is performed
last. The rationale of such a strategy is to control the
CRLM at the same time as the colorectal primary,
optimize the chances of a curative liver resection, and
allow unhurried chemoradiotherapy before rectal sur-
gery when indicated. All patients had complete colo-
noscopy, endoscopic ultrasonography for rectal
cancers, abdominal and chest computed tomography
(CT) and magnetic resonance imaging (MRI) of the
liver. After multidisciplinary evaluation, eligible
patients were informed on the rationale of the strategy
and accepted the protocol. Data were collected pro-
spectively in an institutionally approved database.
Patients received 3–6 courses of chemotherapy before
liver resection. The chemotherapy regimen used in our
center was mainly OCFL or since 2006 OCFL-B or C
(Oxaliplatine-CPT11- 5FU-Leucovorin plus Bev-
acizumab or Cetuximab). Radiological studies to assess
the response to chemotherapy were done during the
third course. When the patient was considered resect-
able with a decrease in the CEA level, we planned the
liver surgery 2–3 weeks after the third course of chemo-
therapy. Additional courses of chemotherapy were
given only if further response was likely to confer a
surgical advantage.
58 patients with an advanced cancer disease (50% not
initially resectable) were submitted to this neoadjuvant
chemotherapy before a RO resection of the liver metas-
tases (frequently with the use of portal embolisation or
2-stage hepatectomy). 29 patients had a rectal cancer
and received a pelvic radiochemotherapy after the
removal of all liver metastases and before the resection
of the primary tumor. An adjuvant chemotherapy was
given according to the histological response of the pre-
vious chemotherapy. Follow-up consisted of monitor-
ing of tumor markers, endoscopic surveillance and CT.
Recurrences were treated with surgery, radiofrequency
ablation and chemotherapy as appropriate. For the 58
patients, the median number of liver metastases was 6
(2-21). The median size was 6 cm (1-14). Bilobar
metastases were present in 70% of the patients. The
clinical risk score was 3 to 5 (mean 3.7). 50 out of the
58 patients with no extra-hepatic disease completed all
the program (86%). 8 patients (14%) had no resection
with 6 deaths within the first year. The overall survival
of the 50 patients who completed the program was
100% at 1-year, 62% at 3-year and 48% at 5-year. The
reverse strategy (or liver first approach) is a high-
impact chemotherapy followed by resection of liver
metastases before removal of the primary tumour.
This approach seems to be associated with an increased
rate of curative resection and improved long-term sur-
vival without detrimental effect on the evolution of the
primary when a precise schedule is respected. These
patients are very sick and cancer is likely to recur. Con-
servative radical hepatectomies are appropriate in order
to treat potential liver recurrences. The chance of a
cure is dictated by a good timing with all steps
planned in advance. The reverse strategy for patients
with advanced synchronous liver metastases allowed in
this series to downstage the CRM in 80% of the
cases, to select patients with responding disease avoid-
ing unnecessary surgery to deliver state of the art pre-
operative rectal radiotherapy without the fear that liver
metastases will meanwhile progress beyond the possibil-
ity of cure.
De09-2
SYNCHRONOUS COLORECTAL
CANCER LIVER METASTASIS: IS
SIMULTANEOUS LIVER RESECTION
DESIRABLE?
Marcos Perini
University of S~ao Paulo Medical School, Brazil
Synchronous colorectal cancer with liver metastasis
(SCLM) represents a challenge for both surgeons and
oncologists once 15-25% of patients diagnosed with
colon cancer present metastatic liver disease(Manfredi,
Lepage et al. 2006). Nowadays, margin negative resec-
tion is the gold standard treatment, despite the
advances in chemotherapy(Nordlinger, Sorbye et al.
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2008). Simultaneous approach (SA) involves the resec-
tion of the primary tumor and the liver metastasis (with
or with neoadjuvant chemotherapy) and contra pose to
the classical colon first approach (CA). Reversal
approach (RA) in which the metastatic liver disease is
resected first is another therapeutic option that could
be used in a minority of cases presenting with rectal
cancer in which the amount of liver disease precludes a
safe and margin free resection (Mentha, Majno et al.
2006). After the advances in peri-operative manage-
ment, simultaneous liver and colon resection (SLCR)
has been proposed in many cases with acceptable mor-
bi-mortality and comparable survival(Minagawa, Mak-
uuchi et al. 2000; Martin, Paty et al. 2003; Weber,
Bachellier et al. 2003; de Santibanes, Fernandez et al.
2010). Even more, some can argue that simultaneous
resection in selected cases carries advantages such
reduced length of hospital stay and costs over the clas-
sical approach. In which patient SLCR should be per-
formed is still a matter of debate, but most
hepatobiliary surgeons agree that specialized teams
should do it. Regarding the type of resection most
commonly performed in the simultaneous approach,
there is a preponderance of colonic over rectal tumors
and minor over major liver resections. Most of cases
have unilateral liver disease and neoadjuvant chemo-
therapy was performed in less than one third of the
cases when compared to the classical approach. Con-
trary, most cases submitted to reversal approach had
chemotherapy before resection - around 75% (Mayo,
Pulitano et al. 2013). Many series have compared major
liver resections regarding staged vs. simultaneous
approach. Mortality rates were similar in in the two
groups and when considering the two hospitalizations,
morbidity and hospital stay were even lower in the
simultaneous group(Capussotti, Ferrero et al. 2007;
Martin, Augenstein et al. 2009; Luo, Wang et al. 2010).
Data from one large multicentric retrospective study
involving 1004 patients showed that for patients under-
going a major hepatectomy, there was no difference in
overall complications between groups. Although the
SLCR group had a higher incidence of mortality (8%
vs. 2.8%) it was not statistically significant(Mayo,
Pulitano et al. 2013). One question that still needs fur-
ther investigation is the use of pre-operative chemother-
apy in patients with resectable disease at presentation
(Nordlinger, Sorbye et al. 2008). The theoretical advan-
tage of time test (tumor behavior) and eradication of
micrometastatic disease is opposed to the liver injury
secondary to its use. Although the drawbacks could be
overcome by two-stage hepatectomy or portal vein
embolization, parenchymal liver injury is a major con-
cern when dealing with patients having more than 6
cycles of oxaliplatin/irinotecan(Karoui, Penna et al.
2006). Moreover, two retrospective series failed to dem-
onstrate any survival advantage in patients with syn-
chronic liver metastasis submitted to simultaneous liver
and colonic resection that had neoadjuvant chemother-
apy(Allen, Kemeny et al. 2003; Reddy, Zorzi et al.
2009). In order to better stratify patients in whom neo-
adjuvant chemotherapy could be useful, risk scores
were proposed(Fong, Fortner et al. 1999). Indications
for neoadjuvant chemotherapy in patients with SCLM
are: patients with more than 3 lymph node metastasis,
advanced rectal tumors (T4 or T3N+) and presence of
extra-hepatic disease. In these patients, neoadjuvant
chemotherapy seems to be reasonable but further stud-
ies are needed(Minagawa, Makuuchi et al. 2000; Cap-
ussotti, Vigano et al. 2007). The effectiveness of new
drugs (response rates ranging from 30-70%) is challeng-
ing the use of radiotherapy in mid/low rectal cancer.
Despite being the gold standard treatment of advanced
distal rectal lesions (T3/4 and N+), radiotherapy lacks
systemic effect and local complications are quite com-
mon(Kapiteijn, Marijnen et al. 2001). On the other
hand, with new drugs, systemic chemotherapy is as
effective as radiotherapy in tumor response and spares
patients unnecessary side effects. Stronger evidence
should be studied in order to propose the best
approach in patients with SCLM(Vigano, Langella et
al. 2013). Simultaneous laparoscopic resection of colon
and liver is feasible and many case series have shown
good results. Lesions located in the antero-lateral seg-
ments are more prone to laparoscopic resection, but
even major resections have been performed by special-
izes centers. Despite the lack of high quality evidence
and survival data, it can be considered in a small subset
of well-selected cases. As demonstrated by retrospective
studies and meta-analysis, long-term outcomes of over-
all and recurrence-free survival are similar when SCLM
is compared to the classical approach(Yin, Liu et al.
2013). When comparing the three approaches (classical,
simultaneous and reversal) some studies have shown
that the operative strategy had no impact on long-term
outcomes, showing the importance of tumor behavior
over the technical assessment(Brouquet, Mortenson et
al. 2010; Mayo, Pulitano et al. 2013). Reversal
approach may be a particularly beneficial in patients
with a large amount o liver disease (but potentially
resectable) and advanced rectal tumors, in order to not
delay systemic treatment. Despite rational and widely
discussed, until now only few studies (three observa-
tional and one retrospective cohort) have been pub-
lished regarding reversal approach involving at all 91
patients(Mentha, Roth et al. 2008; Verhoef, van der
Pool et al. 2009; Brouquet, Mortenson et al. 2010; de
Jong, van Dam et al. 2011). Summarizing, simultaneous
resection of colorectal liver metastasis is safe and feasi-
ble and should be considered in the treatment of
selected patients with metastatic colorectal cancer in
specialized centers.
De10-1
SHOULD WE DO ADULT LDLT FOR
ACUTE ON CHRONIC LIVER
FAILURE?/EASTERN PERSPECTIVE
Shinji Uemoto
Kyoto University, Japan
Acute on chronic liver failure (ACLF) is serious condi-
tion with varied etiology, and any patients who had
underlying chronic liver disease with superimposed
acute insult is being labeled as ACLF. However, most
people raised the concern that this would lead to over-
lap with decompensated liver disease. Recently, APASL
determined the definition of ACLF as acute hepatic
insult manifesting as jaundice and coagulopathy, com-
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 50–58
56 Debate
plicated within 4 weeks by ascites and/or encephalopa-
thy in a patient with previously diagnosed or undiag-
nosed chronic liver disease. Definition of the liver
failure in ACLF is the following: jaundice (serum bili-
rubin > 5 mg/dl) and coagulopathy (INR >1.5 or pro-
thrombin activity <40%) are mandatory/ ascites and/or
encephalopathy as determined by physical examination.
Between January 2000 and December 2012, 677 cases
of adult LDLT were performed at Kyoto University
Hospital, in which 12 cases (2%) were ACLF according
to the APASL criteria. Etiologies of ACLF were hepa-
titis B virus (HBV) in 7 cases, primary biliary cirrhosis
(PBC) in 4, and unknown in one. Six male and 6
female, and mean ages were 49 years old. Nine patients
received right lobe grafts and 3 left, and mean GRWR
was 1.04. ABO-blood combinations were 6 identical, 3
compatible, and 3 incompatible. One recipients died of
graft failure 11 months after transplantation, but the
remaining 11 survived until now (survival rate : 92%).
On the other hands, recipient survival in all adult
LDLT was 66% (449 out of 677 recipients) during the
same period. Recent several reports describing outcome
of LDLT for ACLF in eastern countries demonstrated
acceptable results, which are comparable to that from
non-ACLF patients. Judging from our experience and
recent reports in the literatures, ACLF is a good indi-
cation for LDLT.
De11-2
RADIOFREQUENCY ABLATION OF
EARLY STAGE HEPATOCELLULAR
CARCINOMA
Hyunchul Rhim
Samsung Medical Center, Sungkyunkwan University,
Korea
Resection is the first-line treatment option for patient
with solitary HCC and well-preserved liver function.
Local ablation with radiofrequency or ethanol injection
is considered the standard of care for the patients with
very early or early HCC not suitable for surgery. Both
techniques achieve complete responses in most of cases
with good long-term outcomes especially for the
patients with very early stage HCC. The advantages of
local therapy are the followings: 1) Minimally invasive
procedure, 2) Excellent local tumor control for very
small tumor (<2cm), 3) Repeatable procedure for recur-
rent tumors. However, the cons of local therapy are the
limited tumor control for 1) larger (> 3cm) tumor, 2)
perivascular tumor (heat-sink effect), 3) Inconspicuous
tumor on guiding modality, and 4) Inferior disease free
survival due to continuous intrahepatic recurrence.
Although there are many comparative studies to eluci-
date whether RFA can compete with surgical resection
as a first-line treatment for patients with early HCC,
the results of even RCT studies are conflicting and
there are many limitation in study design to draw any
conclusion. An ongoing RCT with large series (SURF
trial) may provide more robust evidence on which
specific subgroup is ideal for each treatment option.
Radiofrequency ablation has a great potential to
provide an excellent local tumor control with almost-
zero mortality for the patient with unresectable or
untranspantable small HCC. Furthermore, using many
novel techniques with fusion imaging or Contrast-
enhanced US guidance, RFA will extend its role in the
era of multidisciplinary strategy for managing HCC.
De12-2
ROUTINE DRAINAGE FOLLOWING
PANCREATECTOMY: LET’S STOP
TREATING OURSELVES
Andrew Lowy
University of California, U.S.A.
Despite marked improvement in mortality rates follow-
ing pancreatectomy, pancreatic duct leak and subse-
quent intra-abdominal fluid collections remain a source
of major morbidity. The use of drains placed at opera-
tion has been a common practice of pancreatic sur-
geons for decades despite a lack of high-level
supporting evidence. The rationale for and against the
use of drains will be discussed. The presenter will
review the best available evidence examining morbidity
with and without routine drainage following pancrea-
tectomy and will thereby demonstrate that their use is
not warranted. The presenter will review the best avail-
able evidence examining morbidity with and without
routine drainage following pancreaticoduodenectomy.
The presenter will review the best available evidence
examining morbidity with and without routine drainage
following pancreaticoduodenectomy and will thereby
demonstrate that their use is not warranted. The pre-
senter will review the best available evidence examining
morbidity with and without routine drainage following
pancreaticoduodenectomy and will thereby demonstrate
that their use is not warranted.
De14-2
ENDOSCOPIC STENTING FOR
CHRONIC PANCREATITIS
Dirk Gouma
Academic Medical Center, Netherlands
The indication for intervention in chronic pancreatitis
are mainly intractable pain (after conservative treat-
ment) and complications such as biliary obstruction/
stenosis, pseudocysts, more rarely duodenal stenosis
and the risk for malignancy. For the debate I will focus
on the selection of treatment options, endoscopy versus
surgery, for the management of intractable pain. These
patients will generally present with a dilated pancreatic
duct with or without an enlarged mass in the pancreatic
head/tail. Patients with an “inflammatory mass” of
more than 4 cm are generally not considered as candi-
date for endoscopic intervention and will undergo sur-
gery; resection combined with a drainage, preferable a
duodenal preserving procedure (DPPHR). The discus-
sion today will therefore focus on endoscopic drainage
with stents versus surgical drainage for patients with
obstruction of the pancreatic duct. Many retrospective
cohort studies showed that the initial success rate of
endoscopic stenting is high, more than 90%, but long
term pain relief is reported between 48% to 85%
including many re-interventions, stent replacements ,
extra ESWL procedures and in about 10- 20% surgery.
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Cohort studies on surgical drainage by pancreaticojej-
unostomy report a success rate of around 80%. We
performed a RCT comparing endoscopic stenting com-
bined with ESWL versus pancreaticojejunostomy in
symptomatic patients with obstruction of the pancreatic
duct without an inflammatory mass. During the 24
months follow-up patients who underwent surgery had
lower pain scores (main Izbicki pain score 25 vs 51 )
and a better physical healthscore compared with endo-
scopic treatment. The final pain relief score at 24
months was resp. 75% and 32%. After 5 years follow-
up pain relief was still in favour for surgery and 9/19
(47%) of patients with endoscopic treatment still
needed surgical intervention. The overall costs were
higher for endoscopic treatment resp. 31.048 vs 25.042
US dollars for surgery. A Cochrane review and meta-
analysis in 2012 (limitation 2 RCTs) also showed that
surgery was superior to endoscopy for pain relief (RR
1.62, 95% CI 1.11 to 2.37). Despite these findings the
European Society of Gastrointestinal Endoscopy
(ESGE) guidelines still recommend endoscopy as the
first line treatment. A few studies showed already that
long term pain (> 3 yrs) endoscopic treatment (> 5
procedures), opioid use are risk factors associated with
pain relief after surgery. Therefore a multicentre RCT,
the ESCAPE trial, is currently performed in the Neth-
erlands to compare early surgery versus a Step-up prac-
tice (optimal medical treatment, endoscopic treatment ,
surgery) to show also the superiority of surgery in a
group of patients with dilated ducts and moderate
pain. In conclusion: There are currently no data from
RCTs (level I evidence) to support that endoscopic
treatment of patient with chronic pancreatitis is better
than surgery. So far surgery showed to be superior,
with lower overall medical costs and less frequent
hospitalisation.
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